From atheist YouTuber to praying for divine revelation, what has happened to Alex O’Connor?

On The Gospel Coalition website, he uploaded the debate-documentary "Collision," finding the final scene with Wilson and Hitchens especially telling of what Hitchens thought of God and religion. The ...

It’s an ongoing debate on TikTok: A couple wonders why one of them can smell ladybugs and the other can’t. Below that video, one commenter notes that ants smell, too, like a “combo of tomato ...

The debate on his sexuality Freddie Mercury’s sexuality was a complex and often misunderstood aspect of his life. Despite his flamboyant stage persona and relationships with both men and women ...

The Break Down: Insights into North Texas STAAR test results and debates. June 26, 2025 1:35 PM. Stories by Fort Worth Star-Telegram journalists, with AI summarization.

The latest discussions around STAAR test results in North Texas and the implications for education reform as Fort Worth ISD battles a potential state takeover.

After FDA says no, Bayer bags EU nod for twice-yearly Eylea. Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.

Using mRNA to stop HIV from hiding away in white blood cells could be the key to developing a way to eradicate the infection, rather than simply managing viral levels in the body.

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC) ...

Novartis has grown in renal diseases once again with a $1.7bn deal to buy Regulus and its autosomal dominant polycystic kidney disease (ADPKD) drug.

Otsuka, Vera stake their claims to IgAN treatment. Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.